Joann Peters
Seminars
• How to define the right length of vaccine administration in advanced and adjuvant settings to maximize durable immune responses and reduce relapse risk
• How to weigh the trade-offs between prolonged treatment and patient quality of life to avoid unnecessary long-term psychological burden
• How to tailor duration strategies by modality (RNA, DNA, peptides) to minimize side effects and achieve sustained clinical benefit
• Defining scalable QC frameworks for PCVs by identifying which release assays reduce redundancy, batch release time, and regulatory rework at Phase II and beyond
• Applying risk-based release strategies in bespoke manufacturing workflows to enable faster, compliant release of low-volume batches
• Designing digital QA systems early on to support faster QP release as batch volumes increase
